Lenka Sedlarikova
Overview
Explore the profile of Lenka Sedlarikova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
629
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Besse A, Sedlarikova L, Buechler L, Kraus M, Yang C, Strakova N, et al.
Br J Cancer
. 2024 Jul;
131(5):918-930.
PMID: 38969867
Background: Resistance to chemotherapy is a major problem in the treatment of patients with triple-negative breast cancer (TNBC). Preclinical data suggest that TNBC is dependent on proteasomes; however, clinical observations...
2.
Obr A, Klener P, Furst T, Kriegova E, Zemanova Z, Urbankova H, et al.
Br J Haematol
. 2020 Aug;
191(5):e103-e106.
PMID: 32862455
No abstract available.
3.
Sedlarikova L, Petrackova A, Papajik T, Turcsanyi P, Kriegova E
Front Oncol
. 2020 Jul;
10:894.
PMID: 32670873
Inhibitors of B-cell receptor signaling, ibrutinib and idelalisib, and BCL-2 antagonist, venetoclax, have become the mainstay of treatment for chronic lymphocytic leukemia (CLL). Despite significant efficacy in most CLL patients,...
4.
Petrackova A, Minarik J, Sedlarikova L, Libigerova T, Hamplova A, Krhovska P, et al.
Br J Haematol
. 2020 Mar;
189(4):e122-e125.
PMID: 32130732
No abstract available.
5.
Vrabel D, Sedlarikova L, Besse L, Rihova L, Bezdekova R, Almasi M, et al.
Eur J Haematol
. 2019 Nov;
104(3):190-197.
PMID: 31763708
Objectives: Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for...
6.
Petrackova A, Vasinek M, Sedlarikova L, Dyskova T, Schneiderova P, Novosad T, et al.
Front Oncol
. 2019 Sep;
9:851.
PMID: 31552176
The insufficient standardization of diagnostic next-generation sequencing (NGS) still limits its implementation in clinical practice, with the correct detection of mutations at low variant allele frequencies (VAF) facing particular challenges....
7.
Sedlarikova L, Bollova B, Radova L, Brozova L, Jarkovsky J, Almasi M, et al.
Hematol Oncol
. 2018 Aug;
36(5):786-791.
PMID: 30144133
Multiple myeloma is the second most common hematological malignancy characterized by focal lesions of malignant plasma cells in the bone marrow. These lesions contain subclones that directly influence survival of...
8.
Abt D, Besse A, Sedlarikova L, Kraus M, Bader J, Silzle T, et al.
BJU Int
. 2017 Nov;
121(4):600-609.
PMID: 29161753
Objectives: To assess the potential of second-generation proteasome inhibition by carfilzomib and its combination with the human immunodeficiency virus (HIV) protease inhibitors (HIV-PIs) lopinavir and nelfinavir in vitro for improved...
9.
Kubaczkova V, Vrabel D, Sedlarikova L, Besse L, Sevcikova S
Eur J Haematol
. 2017 Jul;
99(4):291-299.
PMID: 28692178
Although tumor cells are the most reliable source of tumor DNA, biopsy of the tumor is an invasive procedure that should be avoided in some cases. The main limitation of...
10.
Sedlarikova L, Gromesova B, Kubaczkova V, Radova L, Filipova J, Jarkovsky J, et al.
Eur J Haematol
. 2017 May;
99(3):223-233.
PMID: 28543758
Objectives: Long non-coding RNAs (lncRNAs) are RNA transcripts longer than 200 nucleotides that are not translated into proteins. They are involved in pathogenesis of many diseases including cancer and have...